746 related articles for article (PubMed ID: 16170080)
1. Epstein-Barr virus and disease activity in multiple sclerosis.
Buljevac D; van Doornum GJ; Flach HZ; Groen J; Osterhaus AD; Hop W; van Doorn PA; van der Meché FG; Hintzen RQ
J Neurol Neurosurg Psychiatry; 2005 Oct; 76(10):1377-81. PubMed ID: 16170080
[TBL] [Abstract][Full Text] [Related]
2. Humoral immune response to EBV in multiple sclerosis is associated with disease activity on MRI.
Farrell RA; Antony D; Wall GR; Clark DA; Fisniku L; Swanton J; Khaleeli Z; Schmierer K; Miller DH; Giovannoni G
Neurology; 2009 Jul; 73(1):32-8. PubMed ID: 19458321
[TBL] [Abstract][Full Text] [Related]
3. Antibodies to Epstein-Barr virus and MRI disease activity in multiple sclerosis.
Kvistad S; Myhr KM; Holmøy T; Bakke S; Beiske AG; Bjerve KS; Hovdal H; Løken-Amsrud KI; Lilleås F; Midgard R; Njølstad G; Pedersen T; Benth JŠ; Wergeland S; Torkildsen O
Mult Scler; 2014 Dec; 20(14):1833-40. PubMed ID: 24842958
[TBL] [Abstract][Full Text] [Related]
4. Epstein-Barr virus antibodies and risk of multiple sclerosis: a prospective study.
Ascherio A; Munger KL; Lennette ET; Spiegelman D; Hernán MA; Olek MJ; Hankinson SE; Hunter DJ
JAMA; 2001 Dec; 286(24):3083-8. PubMed ID: 11754673
[TBL] [Abstract][Full Text] [Related]
5. Prevalence of primary versus reactivated Epstein-Barr virus infection in patients with VCA IgG-, VCA IgM- and EBNA-1-antibodies and suspected infectious mononucleosis.
Nystad TW; Myrmel H
J Clin Virol; 2007 Apr; 38(4):292-7. PubMed ID: 17336144
[TBL] [Abstract][Full Text] [Related]
6. Multiple sclerosis and Epstein-Barr virus.
Levin LI; Munger KL; Rubertone MV; Peck CA; Lennette ET; Spiegelman D; Ascherio A
JAMA; 2003 Mar; 289(12):1533-6. PubMed ID: 12672770
[TBL] [Abstract][Full Text] [Related]
7. Epstein-Barr virus reactivation and multiple sclerosis.
Torkildsen Ø; Nyland H; Myrmel H; Myhr KM
Eur J Neurol; 2008 Jan; 15(1):106-8. PubMed ID: 18042233
[TBL] [Abstract][Full Text] [Related]
8. Measurement of EBV-IgG anti-VCA avidity aids the early and reliable diagnosis of primary EBV infection.
Robertson P; Beynon S; Whybin R; Brennan C; Vollmer-Conna U; Hickie I; Lloyd A
J Med Virol; 2003 Aug; 70(4):617-23. PubMed ID: 12794726
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of Epstein-Barr virus-specific antibodies in Cypriot multiple sclerosis patients.
Deeba E; Koptides D; Gaglia E; Constantinou A; Lambrianides A; Pantzaris M; Krashias G; Christodoulou C
Mol Immunol; 2019 Jan; 105():270-275. PubMed ID: 30562647
[TBL] [Abstract][Full Text] [Related]
10. Temporal relationship between elevation of epstein-barr virus antibody titers and initial onset of neurological symptoms in multiple sclerosis.
Levin LI; Munger KL; Rubertone MV; Peck CA; Lennette ET; Spiegelman D; Ascherio A
JAMA; 2005 May; 293(20):2496-500. PubMed ID: 15914750
[TBL] [Abstract][Full Text] [Related]
11. An altered immune response to Epstein-Barr virus in multiple sclerosis: a prospective study.
Sundström P; Juto P; Wadell G; Hallmans G; Svenningsson A; Nyström L; Dillner J; Forsgren L
Neurology; 2004 Jun; 62(12):2277-82. PubMed ID: 15210894
[TBL] [Abstract][Full Text] [Related]
12. Teriflunomide's effect on humoral response to Epstein-Barr virus and development of cortical gray matter pathology in multiple sclerosis.
Zivadinov R; Ramanathan M; Hagemeier J; Bergsland N; Ramasamy DP; Durfee J; Kolb C; Weinstock-Guttman B
Mult Scler Relat Disord; 2019 Nov; 36():101388. PubMed ID: 31525628
[TBL] [Abstract][Full Text] [Related]
13. Epstein-Barr virus neutralizing and early antigen antibodies in multiple sclerosis.
Lindsey JW; Hatfield LM; Vu T
Eur J Neurol; 2010 Oct; 17(10):1263-9. PubMed ID: 20402753
[TBL] [Abstract][Full Text] [Related]
14. Real-time Epstein-Barr virus PCR for the diagnosis of primary EBV infections and EBV reactivation.
Luderer R; Kok M; Niesters HG; Schuurman R; de Weerdt O; Thijsen SF
Mol Diagn; 2005; 9(4):195-200. PubMed ID: 16392898
[TBL] [Abstract][Full Text] [Related]
15. Schizophrenia is Associated With an Aberrant Immune Response to Epstein-Barr Virus.
Dickerson F; Jones-Brando L; Ford G; Genovese G; Stallings C; Origoni A; O'Dushlaine C; Katsafanas E; Sweeney K; Khushalani S; Yolken R
Schizophr Bull; 2019 Sep; 45(5):1112-1119. PubMed ID: 30462333
[TBL] [Abstract][Full Text] [Related]
16. Serum EBV EA-IgA and VCA-IgA antibodies can be used for risk group stratification and prognostic prediction in extranodal NK/T cell lymphoma: 24-year experience at a single institution.
Huang Y; Rao H; Yan S; Wang F; Wu Q; Feng Y; Zhang Y
Ann Hematol; 2017 Aug; 96(8):1331-1342. PubMed ID: 28550598
[TBL] [Abstract][Full Text] [Related]
17. Evaluation the Architect EBV VCA IgM, VCA IgG, and EBNA-1 IgG chemiluminescent immunoassays to assess EBV serostatus prior transplantation.
Maylin S; Feghoul L; Salmona M; Herda A; Mercier-Delarue S; Simon F; Legoff J
J Med Virol; 2017 Nov; 89(11):2003-2010. PubMed ID: 28661055
[TBL] [Abstract][Full Text] [Related]
18. Plasma viral load of Epstein-Barr virus and risk of multiple sclerosis.
Wagner HJ; Munger KL; Ascherio A
Eur J Neurol; 2004 Dec; 11(12):833-4. PubMed ID: 15667414
[TBL] [Abstract][Full Text] [Related]
19. Epstein-Barr virus infection in peripheral blood mononuclear cells, synovial fluid cells, and synovial membranes of patients with rheumatoid arthritis.
Blaschke S; Schwarz G; Moneke D; Binder L; Müller G; Reuss-Borst M
J Rheumatol; 2000 Apr; 27(4):866-73. PubMed ID: 10782808
[TBL] [Abstract][Full Text] [Related]
20. High incidence of elevated antibody titers to Epstein-Barr virus in patients with uveitis.
Touge C; Agawa H; Sairenji T; Inoue Y
Arch Virol; 2006 May; 151(5):895-903. PubMed ID: 16362642
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]